>Mercado de tumores neuroendócrinos do Médio Oriente e África, por classificação (rede funcional e rede não funcional), local (pulmão, pâncreas, trato gastrointestinal (GI), grau (grau 1 {tumor de baixo grau}, grau 2 {tumor de grau intermédio }, Grau 3 {Tumor de alto grau}), Tipo (Diagnóstico e tratamento), Via de administração (oral e parentérica), Modo de compra (prescrição e sem receita médica (OTC)), Utilizador final (hospitais, clínicas especializadas, Centros de radiação, assistência médica domiciliária e outros), canal de distribuição (licitação direta, farmácias hospitalares, farmácias de retalho, farmácias on-line e outros), país ( África do Sul , Arábia Saudita, Emirados Árabes Unidos, Egito, Israel, Kuwait e resto do Médio Oriente e África) Tendências e previsões da indústria até 2028
Análise de mercado e insights : mercado de tumores neuroendócrinos do Médio Oriente e África
Espera-se que o mercado dos tumores neuroendócrinos ganhe crescimento de mercado no período previsto de 2021 a 2028. A Data Bridge Market Research analisa que o mercado está a crescer com um CAGR de 9,3% no período previsto de 2021 a 2028 e deverá atingir 174,12 milhões de dólares. até 2028. As iniciativas estratégicas dos participantes do mercado e o advento de programas de vacinação em massa para tumores neuroendócrinos serão provavelmente os principais impulsionadores da procura do mercado no período previsto.
O início do tumor ocorre quando o ADN das células saudáveis é danificado, o que faz com que as células se alterem e cresçam de forma descontrolada, formando assim uma massa agregada de células. Um tumor pode ser cancerígeno e benigno. Um tumor cancerígeno maligno cresce e espalha-se para outras partes do corpo se não for encontrado precocemente e tratado. Um tumor benigno pode crescer, mas não se disseminar. Um tumor benigno pode geralmente ser removido com o uso de cirurgia minimamente invasiva sem causar muitos danos. Um tumor neuroendócrino (TNE) começa nas células especializadas do sistema neuroendócrino do organismo. Estas células têm características comuns tanto das células endócrinas produtoras de hormonas como das células nervosas. Encontram-se em todos os órgãos do corpo e são responsáveis por controlar muitas das funções do organismo. Todos os TNE são considerados tumores malignos. A maioria das NET demora muitos anos a desenvolver-se e cresce lentamente.
No entanto, fatores como os efeitos secundários associados aos tratamentos, as necessidades não satisfeitas e o acesso a recursos médicos em diversas regiões, para além do elevado custo do diagnóstico, estão a dificultar o crescimento do mercado dos tumores neuroendócrinos. Por outro lado, os próximos tratamentos direcionados e as crescentes parcerias e colaborações entre os participantes do mercado funcionam como uma oportunidade para o crescimento do mercado dos tumores neuroendócrinos. A falta de políticas de comparticipação e as rigorosas regulamentações governamentais para o desenvolvimento de medicamentos para os tumores neuroendócrinos são os desafios enfrentados no mercado dos tumores neuroendócrinos.
O relatório de mercado de tumores neuroendócrinos fornece detalhes sobre a quota de mercado, novos desenvolvimentos e análise de pipeline de produtos, impacto dos participantes do mercado nacional e localizado, analisa as oportunidades em termos de bolsas de receitas emergentes, alterações nas regulamentações de mercado, aprovações de produtos, decisões estratégicas, lançamentos de produtos, expansões geográficas e inovações tecnológicas no mercado. Para compreender a análise e o cenário de mercado, contacte-nos para um Briefing de Analista.
Âmbito e dimensão do mercado de tumores neuroendócrinos
O mercado dos tumores neuroendócrinos está segmentado com base na classificação, local, grau, tipo, via de administração, utilizador final e canal de distribuição. O crescimento entre segmentos ajuda-o a analisar os nichos de crescimento e as estratégias para abordar o mercado e determinar as suas principais áreas de aplicação e a diferença nos seus mercados-alvo.
- Com base na classificação , o mercado dos tumores neuroendócrinos está segmentado em rede funcional e rede não funcional. Em 2021, o segmento das redes não funcionais está a dominar o mercado dos tumores neuroendócrinos devido à facilidade de identificação e diagnóstico e à utilização de novos métodos de diagnóstico para remover a rede não funcional.
- Com base na localização, o mercado dos tumores neuroendócrinos está segmentado em pulmão , pâncreas e trato gastrointestinal (GI). Em 2021, o segmento do trato gastrointestinal (GI) está a dominar o mercado dos tumores neuroendócrinos devido ao aumento da prevalência do cancro gástrico e a presença de um forte pipeline de produtos deverá dominar o mercado.
- Com base no grau, o mercado dos tumores neuroendócrinos está segmentado em grau 1 (tumor de baixo grau), grau 2 (tumor de grau intermédio) e grau 3 (tumor de alto grau). Em 2021, o segmento de grau 2 (tumor de grau intermédio) está a dominar o mercado dos tumores neuroendócrinos, uma vez que pode ser facilmente curado por tratamentos terapêuticos e prevê-se que o aumento de casos de grau 2 (tumor de grau intermédio) domine o mercado.
- Com base no tipo, o mercado dos tumores neuroendócrinos está segmentado em diagnóstico e tratamento. Em 2021, prevê-se que o segmento de diagnóstico domine o mercado dos tumores neuroendócrinos devido ao aumento da incidência de tumores de cancro do pâncreas e à maior adoção do diagnóstico automatizado no ponto de atendimento no mercado.
- Com base na via de administração, o mercado dos tumores neuroendócrinos está segmentado em oral e parentérica. Em 2021, prevê-se que o segmento oral domine o mercado dos tumores neuroendócrinos devido à disponibilidade de medicamentos na forma oral, maior adesão dos doentes e facilidade de absorção.
- Com base no utilizador final, o mercado dos tumores neuroendócrinos está segmentado em hospitais, clínicas especializadas, centros de radiação, cuidados de saúde domiciliários e outros. Em 2021, prevê-se que o segmento hospitalar domine o mercado dos tumores neuroendócrinos devido à disponibilidade de máquinas de diagnóstico para detetar tumores neuroendócrinos e à disponibilidade de políticas de saúde.
- Com base no canal de distribuição, o mercado dos tumores neuroendócrinos está segmentado em licitação direta, farmácia hospitalar, farmácia de retalho, farmácia online e outros. Em 2021, prevê-se que o segmento de licitação direta domine o mercado dos tumores neuroendócrinos devido ao aumento de fornecedores no mercado.
Análise do mercado de tumores neuroendócrinos a nível de país
O mercado dos tumores neuroendócrinos é analisado e são fornecidas informações sobre o tamanho do mercado, classificação, local, grau, tipo, via de administração, utilizador final e canal de distribuição, conforme referenciado acima.
Os países abrangidos pelo relatório de mercado sobre tumores neuroendócrinos são a África do Sul, Arábia Saudita, Emirados Árabes Unidos, Egito, Kuwait, Israel e o resto do Médio Oriente e África.
Prevê-se que o Médio Oriente e África cresçam a uma taxa de crescimento substancial no período previsto de 2021 a 2028, uma vez que os países do Médio Oriente e África são grandes países em desenvolvimento e concentram-se no aumento das actividades de I&D nos setores farmacêutico e biotecnológico e no aumento dos serviços de outsourcing. Prevê-se que a África do Sul domine a região do Médio Oriente e África devido aos avanços tecnológicos na detecção de tumores neuroendócrinos.
A secção do relatório sobre os países também fornece fatores individuais que impactam o mercado e alterações na regulamentação do mercado nacional que impactam as tendências atuais e futuras do mercado. Pontos de dados como novas vendas, vendas de reposição, demografia do país, atos regulamentares e tarifas de importação e exportação são alguns dos principais indicadores utilizados para prever o cenário de mercado para países individuais. Além disso, a presença e a disponibilidade de marcas globais e os desafios enfrentados devido à grande ou escassa concorrência de marcas locais e nacionais, bem como o impacto dos canais de vendas, são considerados ao fornecer uma análise de previsão dos dados do país.
O aumento das iniciativas governamentais e as crescentes colaborações dos participantes do mercado estão a criar novas oportunidades no mercado dos tumores neuroendócrinos
O mercado de tumores neuroendócrinos também fornece uma análise detalhada do mercado para o crescimento de cada país num setor específico com vendas de tumores neuroendócrinos, impacto do avanço nos tumores neuroendócrinos e mudanças nos cenários regulamentares com o seu apoio ao mercado de tumores neuroendócrinos. Os dados estão disponíveis para o período histórico de 2010 a 2019.
Análise do panorama competitivo e da quota de mercado dos tumores neuroendócrinos
O panorama competitivo do mercado de tumores neuroendócrinos fornece detalhes por concorrente. Os detalhes incluídos são a visão geral da empresa, finanças da empresa, receitas geradas, potencial de mercado, investimento em investigação e desenvolvimento, novas iniciativas de mercado, localizações e instalações de produção, pontos fortes e fracos da empresa, lançamento de produtos, pipelines de testes de produto, aprovações de produto, patentes, largura e amplitude do produto, domínio da aplicação, curva de vida da tecnologia. Os pontos de dados fornecidos acima estão apenas relacionados com o foco da empresa no mercado dos tumores neuroendócrinos.
As principais empresas no mercado dos tumores neuroendócrinos são a Novartis AG, Bristol-Myers Squibb Company, Pfizer Inc., GlaxoSmithKline plc, Thermo Fisher Scientific Inc., Hutchison China MediTech Limited, F. Hoffmann-La Roche Ltd, Bionano Genomics, Teva Pharmaceutical Industries Ltd. ., Merck Sharp & Dohme Corp., uma subsidiária da Merck & Co., Inc., Sun Pharmaceutical Industries Ltd., Illumina, Inc. e LUPIN, entre outros participantes globais ou nacionais. Os analistas do DBMR compreendem os pontos fortes competitivos e fornecem análises competitivas para cada concorrente em separado.
Muitos lançamentos de produtos e acordos são também iniciados por empresas de todo o mundo, o que está também a acelerar o mercado dos tumores neuroendócrinos.
Por exemplo,
- Em janeiro de 2018 , a Novartis AG tinha proclamado que a Advanced Accelerator Applications, uma subsidiária da Novartis AG, tinha recebido a aprovação da FDA para o seu novo pedido de medicamento Lutathera (lutécio Lu 177 dotatate*) para o tratamento de tumores neuroendócrinos gastroenteropancreáticos positivos para os recetores de somatostatina (GEP-NETs). incluindo tumores neuroendócrinos do intestino anterior, médio e posterior em adultos. A aprovação da FDA recebida pela empresa resultou no aumento dos ensaios clínicos, na melhoria do portfólio de produtos oncológicos em neurologia e proporcionaria um crescimento positivo no mercado.
A colaboração, as joint ventures e outras estratégias do participante no mercado estão a aumentar o mercado da empresa no mercado dos tumores neuroendócrinos, o que também traz o benefício para a organização melhorar a sua oferta de tratamento.
SKU-
Obtenha acesso online ao relatório sobre a primeira nuvem de inteligência de mercado do mundo
- Painel interativo de análise de dados
- Painel de análise da empresa para oportunidades de elevado potencial de crescimento
- Acesso de analista de pesquisa para personalização e customização. consultas
- Análise da concorrência com painel interativo
- Últimas notícias, atualizações e atualizações Análise de tendências
- Aproveite o poder da análise de benchmark para um rastreio abrangente da concorrência
Índice
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET: SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 CLASSIFICATION LIFELINE CURVE
2.8 DBMR MARKET POSITION GRID
2.9 VENDOR SHARE ANALYSIS
2.1 MARKET END USER COVERAGE GRID
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
5 PIPELINE ANALYSIS
6 PRICING ANALYSIS
7 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET: REGULATIONS
7.1 REGULATORY PROCEDURE IN THE U.S.
7.2 REGULATORY PROCEDURE IN CANADA
7.3 REGULATORY PROCEDURE IN EUROPE
7.4 REGULATORY PROCEDURE IN CHINA
7.5 REGULATORY PROCEDURE IN MIDDLE EAST AND AFRICA
8 COMPARITIVE ANALYSIS BETWEEN MONOCLONAL AND POLYCLONAL ANTIBODY
8.1 MONOCLONAL ANTIBODY
8.2 POLYCLONAL ANTIBODY
9 MARKET OVERVIEW
9.1 DRIVERS
9.1.1 INCREASED INCIDENCE OF NEUROENDOCRINE TUMOR CASES
9.1.2 TECHNOLOGICAL ADVANCEMENT FOR THE DETECTION OF NEUROENDOCRINE TUMORS
9.1.3 GROWTH IN THE NUMBER OF PRIVATE DIAGNOSTIC CENTERS AND TREATMENT PROVIDERS
9.1.4 PRESENCE OF TARGETED TREATMENT OPTIONS
9.1.5 FAVORABLE REIMBURSEMENT POLICIES
9.2 RESTRAINTS
9.2.1 HIGH CAPITAL INVESTMENTS & LOW BENEFIT-COST RATIO FOR BIOMARKERS AND ORPHAN DRUGS
9.2.2 LACK OF AWARENESS AMONG THE POPULATION
9.2.3 UNMET NEEDS AND ACCESS TO MEDICAL RESOURCES IN SEVERAL REGIONS
9.2.4 HIGH COST OF DIAGNOSIS
9.3 OPPORTUNITIES
9.3.1 INCREASED GOVERNMENT INITIATIVES
9.3.2 EMERGING THERAPIES & DEVELOPMENT IN TREATMENT
9.3.3 RISING COLLABORATIONS AMONG THE MARKET PLAYERS
9.4 CHALLENGES
9.4.1 SIDE EFFECTS ASSOCIATED WITH TREATMENTS
9.4.2 STRINGENT GOVERNMENT REGULATIONS FOR THE DEVELOPMENT OF NEUROENDOCRINE TUMOR DRUGS
10 IMPACT OF COVID 19 ON MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET
10.1 PRICE IMPACT
10.2 IMPACT OF DEMAND
10.3 IMPACT ON SUPPLY CHAIN:
10.4 STRATEGIC DECISIONS:
10.5 CONCLUSION:
11 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION
11.1 OVERVIEW
11.2 NON-FUNCTIONAL NET
11.3 FUNTIONAL NET
12 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET, BY SITE
12.1 OVERVIEW
12.2 GASTROINTESTINAL TRACT (GI)
12.3 LUNGS
12.4 PANCREAS
13 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET, BY GRADE
13.1 OVERVIEW
13.2 GRADE 2 (INTERMEDIATE-GRADE TUMOR)
13.3 GRADE 3 (HIGH-GRADE TUMOR)
13.4 GRADE 1( LOW-GRADE TUMOR)
14 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET, BY TYPE
14.1 OVERVIEW
14.2 DIAGNOSIS
14.2.1 BLOOD TEST
14.2.2 IMAGING TEST
14.2.2.1 CTSCAN
14.2.2.2 MRI
14.2.2.3 OTHERS
14.2.3 BIOPSY
14.2.4 URINE TEST
14.2.5 OTHERS
14.3 TREATMENT
14.3.1 SOMATOSTATIN ANALOGS
14.3.1.1 OCTREOTIDE
14.3.1.2 LANREOTIDE
14.3.2 TARGETED THERAPY
14.3.2.1 EVEROLIMUS
14.3.2.2 SUNITINIB
14.3.2.3 OTHERS
14.3.3 RADIATION THERAPY
14.3.3.1 EXTERNAL-BEAM RADIATION
14.3.3.2 INTERNAL-BEAM RADIATION
14.3.4 SURGERY
14.3.4.1 CHOLECYSTECTOMY
14.3.4.2 OTHERS
14.3.5 LIVER-DIRECTED TREATMENT
14.3.5.1 RADIO FREQUENCY ABLATION (RFA)
14.3.5.2 HEPATIC ARTERY EMBOLIZATION
14.3.5.3 RADIOEMBOLIZATION
14.3.6 PEPTIDE RECEPTOR RADIONUCLIDE THERAPY (PRRT)/ LUTATHERA
15 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION
15.1 OVERVIEW
15.2 ORAL
15.2.1 TABLETS
15.2.2 PILLS
15.2.3 OTHERS
15.3 PARENTERAL
15.3.1 SUBCUTANEOUS
15.3.2 INTRAMUSCULAR
15.3.3 OTHERS
16 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET, BY END USER
16.1 OVERVIEW
16.2 HOSPITALS
16.3 SPECIALITY CLINICS
16.4 RADIATION CENTERS
16.5 HOME HEALTHCARE
16.6 OTHERS
17 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL
17.1 OVERVIEW
17.2 DIRECT TENDER
17.3 HOSPITAL PHARMACY
17.4 RETAIL SALES
17.5 ONLINE PHARMACY
17.6 OTHERS
18 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET, BY GEOGRAPHY
18.1 MIDDLE EAST AND AFRICA
18.1.1 SOUTH AFRICA
18.1.2 SAUDI ARABIA
18.1.3 EGYPT
18.1.4 ISRAEL
18.1.5 UAE
18.1.6 KUWAIT
18.1.7 REST OF MIDDLE EAST AND AFRICA
19 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET: COMPANY LANDSCAPE
19.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA
20 SWOT
21 COMPANY PROFILES
21.1 F. HOFFMANN-LA ROCHE LTD
21.1.1 COMPANY SNAPSHOT
21.1.2 REVENUE ANALYSIS
21.1.3 COMPANY SHARE ANALYSIS
21.1.4 PRODUCT PORTFOLIO
21.1.5 RECENT DEVELOPMENTS
21.2 BRISTOL-MYERS SQUIBB COMPANY
21.2.1 COMPANY SNAPSHOT
21.2.2 REVENUE ANALYSIS
21.2.3 COMPANY SHARE ANALYSIS
21.2.4 PRODUCT PORTFOLIO
21.2.5 RECENT DEVELOPMENTS
21.3 VIATRIS INC.
21.3.1 COMPANY SNAPSHOT
21.3.2 COMPANY SHARE ANALYSIS
21.3.3 PRODUCT PORTFOLIO
21.3.4 RECENT DEVELOPMENTS
21.4 THERMO FISHER SCIENTIFIC INC.
21.4.1 COMPANY SNAPSHOT
21.4.2 REVENUE ANALYSIS
21.4.3 COMPANY SHARE ANALYSIS
21.4.4 PRODUCT PORTFOLIO
21.4.5 RECENT DEVELOPMENTS
21.5 NOVARTIS AG
21.5.1 COMPANY SNAPSHOT
21.5.2 REVENUE ANALYSIS
21.5.3 COMPANY SHARE ANALYSIS
21.5.4 PRODUCT PORTFOLIO
21.5.5 RECENT DEVELOPMENTS
21.6 REGENERON PHARMACEUTICALS, INC.
21.6.1 COMPANY SNAPSHOT
21.6.2 REVENUE ANALYSIS
21.6.3 PRODUCT PORTFOLIO
21.6.4 RECENT DEVELOPMENTS
21.7 ADVANCED ACCELERATOR APPLICATIONS (A SUBSIDIARY OF NOVARTIS AG)
21.7.1 COMPANY SNAPSHOT
21.7.2 REVENUE ANALYSIS
21.7.3 PRODUCT PORTFOLIO
21.7.4 RECENT DEVELOPMENTS
21.8 BIONANO GENOMICS
21.8.1 COMPANY SNAPSHOT
21.8.2 PRODUCT PORTFOLIO
21.8.3 RECENT DEVELOPMENTS
21.9 BIOSYNTHEMA INC.
21.9.1 COMPANY SNAPSHOT
21.9.2 PRODUCT PORTFOLIO
21.9.3 RECENT DEVELOPMENTS
21.1 CALLISTOPHARMA
21.10.1 COMPANY SNAPSHOT
21.10.2 PRODUCT PORTFOLIO
21.10.3 RECENT DEVELOPMENTS
21.11 ELI LILLY AND COMPANY
21.11.1 COMPANY SNAPSHOT
21.11.2 REVENUE ANALYSIS
21.11.3 PRODUCT PORTFOLIO
21.11.4 RECENT DEVELOPMENTS
21.12 EXACT SCIENCES CORPORATION
21.12.1 COMPANY SNAPSHOT
21.12.2 REVENUE ANALYSIS
21.12.3 PRODUCT PORTFOLIO
21.12.4 RECENT DEVELOPMENTS
21.13 GLAXOSMITHKLINE PLC
21.13.1 COMPANY SNAPSHOT
21.13.2 REVENUE ANALYSIS
21.13.3 PRODUCT PORTFOLIO
21.13.4 RECENT DEVELOPMENTS
21.14 HUTCHISON CHINA MEDITECH LIMITED
21.14.1 COMPANY SNAPSHOT
21.14.2 REVENUE ANALYSIS
21.14.3 PRODUCT PORTFOLIO
21.14.4 RECENT DEVELOPMENTS
21.15 IPSEN PHARMA
21.15.1 COMPANY SNAPSHOT
21.15.2 REVENUE ANALYSIS
21.15.3 PRODUCT PORTFOLIO
21.15.4 RECENT DEVELOPMENTS
21.16 ILLUMINA, INC.
21.16.1 COMPANY SNAPSHOT
21.16.2 REVENUE ANALYSIS
21.16.3 PRODUCT PORTFOLIO
21.16.4 RECENT DEVELOPMENTS
21.17 LUPIN
21.17.1 COMPANY SNAPSHOT
21.17.2 REVENUE ANALYSIS
21.17.3 PRODUCT PORTFOLIO
21.17.4 RECENT DEVELOPMENTS
21.18 MERCK SHARP & DOHME CORP., A SUBSIDIARY OF MERCK & CO., INC.
21.18.1 COMPANY SNAPSHOT
21.18.2 REVENUE ANALYSIS
21.18.3 PRODUCT PORTFOLIO
21.18.4 RECENT DEVELOPMENTS
21.19 PFIZER INC.
21.19.1 COMPANY SNAPSHOT
21.19.2 REVENUE ANALYSIS
21.19.3 PRODUCT PORTFOLIO
21.19.4 RECENT DEVELOPMENTS
21.2 SUN PHARMACEUTICAL INDUSTRIES LTD.
21.20.1 COMPANY SNAPSHOT
21.20.2 REVENUE ANALYSIS
21.20.3 PRODUCT PORTFOLIO
21.20.4 RECENT DEVELOPMENTS
21.21 TEVA PHARMACEUTICAL INDUSTRIES LTD.
21.21.1 COMPANY SNAPSHOT
21.21.2 REVENUE ANALYSIS
21.21.3 PRODUCT PORTFOLIO
21.21.4 RECENT DEVELOPMENTS
22 QUESTIONNAIRE
23 RELATED REPORTS
Lista de Tabela
TABLE 1 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET, PIPELINE ANALYSIS
TABLE 2 SALES DATA OF ONCOLOGY MARKET FOR 2019/2020
TABLE 3 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION 2019-2028(USD MILLION)
TABLE 4 MIDDLE EAST AND AFRICA NON-FUNCTIONAL NET IN NEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION 2019-2027 (USD MILLION)
TABLE 5 MIDDLE EAST AND AFRICA FUNCTIONAL NET IN NEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION 2019-2027 (USD MILLION)
TABLE 6 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET, BY SITE 2019-2028 (USD MILLION)
TABLE 7 MIDDLE EAST AND AFRICA GASTROINTESTINAL TRACT (GI) IN NEUROENDOCRINE TUMORS MARKET, BY SITE 2019-2028 (USD MILLION)
TABLE 8 MIDDLE EAST AND AFRICA LUNGS IN NEUROENDOCRINE TUMORS MARKET, BY SITE 2019-2028 (USD MILLION)
TABLE 9 MIDDLE EAST AND AFRICA PANCREAS NEUROENDOCRINE TUMORS MARKET, BY SITE 2019-2028 (USD MILLION)
TABLE 10 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET, BY GRADE 2019-2028 (USD MILLION)
TABLE 11 MIDDLE EAST AND AFRICA GRADE 2 (INTERMEDIATE-GRADE TUMOR) IN NEUROENDOCRINE TUMORS MARKET, BY GRADE 2019-2028 (USD MILLION)
TABLE 12 MIDDLE EAST AND AFRICA GRADE 3 (HIGH-GRADE TUMOR) IN NEUROENDOCRINE TUMORS MARKET, BY GRADE 2019-2028 (USD MILLION)
TABLE 13 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET, BY GRADE 2019-2028 (USD MILLION)
TABLE 14 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 15 MIDDLE EAST AND AFRICA DIAGNOSIS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 16 MIDDLE EAST AND AFRICA DIAGNOSIS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 17 MIDDLE EAST AND AFRICA IMAGING TEST IN NEUROENDOCRINE TUMORS MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 18 MIDDLE EAST AND AFRICA TREATMENT NEUROENDOCRINE TUMORS MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 19 MIDDLE EAST AND AFRICA TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 20 MIDDLE EAST AND AFRICA SOMATOSTATIN ANALOGS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 21 MIDDLE EAST AND AFRICA TARGETED THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 22 MIDDLE EAST AND AFRICA RADIATION THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 23 MIDDLE EAST AND AFRICA SURGERY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 24 MIDDLE EAST AND AFRICA LIVER-DIRECTED TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 25 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 26 MIDDLE EAST AND AFRICA ORAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 27 MIDDLE EAST AND AFRICA ORAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 28 MIDDLE EAST AND AFRICA PARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 29 MIDDLE EAST AND AFRICA PARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 30 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 31 MIDDLE EAST AND AFRICA HOSPITALS IN NEUROENDOCRINE TUMORS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 32 MIDDLE EAST AND AFRICA SPECIALITY CLINICS IN NEUROENDOCRINE TUMORS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 33 MIDDLE EAST AND AFRICA RADIATION CENTERS IN NEUROENDOCRINE TUMORS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 34 MIDDLE EAST AND AFRICA OTHERS IN RADIOTHERAPY MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 35 MIDDLE EAST AND AFRICA OTHERS IN NEUROENDOCRINE TUMORS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 36 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 37 MIDDLE EAST AND AFRICA DIRECT TENDER IN NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 38 MIDDLE EAST AND AFRICA HOSPITAL PHARMACY IN NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 39 MIDDLE EAST AND AFRICA RETAIL SALES IN NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 40 MIDDLE EAST AND AFRICA ONLINE PHARMACY IN NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 41 MIDDLE EAST AND AFRICA OTHERS IN NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 42 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET, COUNTRY, 2021-2028 (USD MILLION)
TABLE 43 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION, 2021-2028 (USD MILLION )
TABLE 44 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET, BY SITE, 2021-2028 (USD MILLION)
TABLE 45 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET, BY GRADE, 2021-2028 (USD MILLION)
TABLE 46 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 47 MIDDLE EAST AND AFRICA DIAGNOSIS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION
TABLE 48 MIDDLE EAST AND AFRICA IMAGING TEST IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 49 MIDDLE EAST AND AFRICA TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 50 MIDDLE EAST AND AFRICA SOMATOSTATIN ANALOGS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 51 MIDDLE EAST AND AFRICA TARGETED THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 52 MIDDLE EAST AND AFRICA RADIATION THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 53 MIDDLE EAST AND AFRICA SURGERY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 54 MIDDLE EAST AND AFRICA LIVER DIRECTED TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 55 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION , 2021-2028 (USD MILLION)
TABLE 56 MIDDLE EAST ORAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 57 MIDDLE EAST AND AFRICA PARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 58 MIDDLE EASTA AND AFRICA NEUROENDOCRINE TUMORS MARKET, BY END USER, 2021-2028 (USD MILLION)
TABLE 59 MIDDLE EAST AND AFRICA PARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
TABLE 60 SOUTH AFRICA NEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION, 2021-2028 (USD MILLION )
TABLE 61 SOUTH AFRICA NEUROENDOCRINE TUMORS MARKET, BY SITE, 2021-2028 (USD MILLION)
TABLE 62 SOUTH AFRICA NEUROENDOCRINE TUMORS MARKET, BY GRADE, 2021-2028 (USD MILLION)
TABLE 63 SOUTH AFRICA NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 64 SOUTH AFRICA DIAGNOSIS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 65 SOUTH AFRICA IMAGING TEST IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 66 SOUTH AFRICA TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 67 SOUTH AFRICA SOMATOSTATIN ANALOGS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 68 SOUTH AFRICA TARGETED THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 69 SOUTH AFRICA RADIATION THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 70 SOUTH AFRICA SURGERY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 71 SOUTH AFRICA LIVER DIRECTED TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 72 SOUTH AFRICA NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 73 SOUTH AFRICA ORAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 74 SOUTH AFRICA PARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 75 SOUTH AFRICA NEUROENDOCRINE TUMORS MARKET, BY END USER, 2021-2028 (USD MILLION)
TABLE 76 SOUTH AFRICA PARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
TABLE 77 SAUDI ARABIA NEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION, 2021-2028 (USD MILLION)
TABLE 78 SAUDI ARABIA NEUROENDOCRINE TUMORS MARKET, BY SITE, 2021-2028 (USD MILLION)
TABLE 79 SAUDI ARABIA NEUROENDOCRINE TUMORS MARKET, BY GRADE, 2021-2028 (USD MILLION)
TABLE 80 SAUDI ARABIA NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 81 SAUDI ARABIA DIAGNOSIS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 82 SAUDI ARABIA IMAGING TEST IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 83 SAUDI ARABIA TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 84 SAUDI ARABIA SOMATOSTATIN ANALOGS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 85 SAUDI ARABIA TARGETED THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 86 SAUDI ARABIA RADIATION THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 87 SAUDI ARABIA SURGERY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 88 SAUDI ARABIA LIVER DIRECTED TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 89 SAUDI ARABIA NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 90 SAUDI ARABIA ORAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 91 SAUDI ARABIA PARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 92 SAUDI ARABIA NEUROENDOCRINE TUMORS MARKET, BY END USER, 2021-2028 (USD MILLION)
TABLE 93 SAUDI ARABIA PARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
TABLE 94 EGYPT EUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION, 2021-2028 (USD MILLION)
TABLE 95 EGYPT NEUROENDOCRINE TUMORS MARKET, BY SITE, 2021-2028 (USD MILLION)
TABLE 96 EGYPT NEUROENDOCRINE TUMORS MARKET, BY GRADE, 2021-2028 (USD MILLION)
TABLE 97 EGYPT NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 98 EGYPT DIAGNOSIS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 99 EGYPT IMAGING TEST IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 100 EGYPT TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 101 EGYPT SOMATOSTATIN ANALOGS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 102 EGYPT TARGETED THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 103 EGYPT RADIATION THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 104 EGYPT SURGERY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 105 EGYPT LIVER DIRECTED TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 106 EGYPT NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 107 EGYPT ORAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 108 EGYPT PARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 109 EGYPT NEUROENDOCRINE TUMORS MARKET, BY END USER, 2021-2028 (USD MILLION)
TABLE 110 EGYPT PARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
TABLE 111 ISRAEL EUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION, 2021-2028 (USD MILLION)
TABLE 112 ISRAEL NEUROENDOCRINE TUMORS MARKET, BY SITE, 2021-2028 (USD MILLION)
TABLE 113 ISRAEL NEUROENDOCRINE TUMORS MARKET, BY GRADE, 2021-2028 (USD MILLION)
TABLE 114 ISRAEL NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 115 ISRAEL DIAGNOSIS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 116 ISRAEL IMAGING TEST IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 117 ISRAEL TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 118 ISRAEL SOMATOSTATIN ANALOGS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 119 ISRAEL TARGETED THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 120 ISRAEL RADIATION THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 121 ISRAEL SURGERY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 122 ISRAEL LIVER DIRECTED TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 123 ISRAEL NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 124 ISRAEL ORAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 125 ISRAEL PARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 126 ISRAEL NEUROENDOCRINE TUMORS MARKET, BY END USER, 2021-2028 (USD MILLION)
TABLE 127 ISRAEL PARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
TABLE 128 UAE EUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION, 2021-2028 (USD MILLION)
TABLE 129 UAE NEUROENDOCRINE TUMORS MARKET, BY SITE, 2021-2028 (USD MILLION)
TABLE 130 UAE NEUROENDOCRINE TUMORS MARKET, BY GRADE, 2021-2028 (USD MILLION)
TABLE 131 UAE NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 132 UAE DIAGNOSIS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 133 UAE IMAGING TEST IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 134 UAE TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 135 UAE SOMATOSTATIN ANALOGS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 136 UAE TARGETED THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 137 UAE RADIATION THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 138 UAE SURGERY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 139 UAE LIVER DIRECTED TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 140 UAE NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 141 UAE ORAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 142 UAE PARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 143 UAE NEUROENDOCRINE TUMORS MARKET, BY END USER, 2021-2028 (USD MILLION)
TABLE 144 UAE PARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
TABLE 145 KUWAIT NEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION, 2021-2028 (USD MILLION)
TABLE 146 KUWAIT NEUROENDOCRINE TUMORS MARKET, BY SITE, 2021-2028 (USD MILLION)
TABLE 147 KUWAIT NEUROENDOCRINE TUMORS MARKET, BY GRADE, 2021-2028 (USD MILLION)
TABLE 148 KUWAIT NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 149 KUWAIT DIAGNOSIS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 150 KUWAIT IMAGING TEST IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 151 KUWAIT TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 152 KUWAIT SOMATOSTATIN ANALOGS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 153 KUWAIT TARGETED THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 154 KUWAIT RADIATION THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 155 KUWAIT SURGERY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 156 KUWAIT LIVER DIRECTED TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 157 KUWAIT NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 158 KUWAIT ORAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 159 KUWAIT PARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 160 KUWAIT NEUROENDOCRINE TUMORS MARKET, BY END USER, 2021-2028 (USD MILLION)
TABLE 161 KUWAIT PARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
TABLE 162 REST OF MIDDLE EAST AND AFRICA EUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION, 2021-2028 (USD MILLION)
Lista de Figura
FIGURE 1 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET: SEGMENTATION
FIGURE 2 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET: DATA TRIANGULATION
FIGURE 3 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET: DROC ANALYSIS
FIGURE 4 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET: MIDDLE EAST AND AFRICA VS REGIONAL ANALYSIS
FIGURE 5 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET: DBMR MARKET POSITION GRID
FIGURE 8 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET: VENDOR SHARE ANALYSIS
FIGURE 9 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET: MARKET END USER COVERAGE GRID
FIGURE 10 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET: SEGMENTATION
FIGURE 11 INCREASED AWARENESS OF NEUROENDOCRINE TUMORS CASES IS EXPECTED TO DRIVE THE MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 12 NON-FUNTIONAL NET SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET IN 2021 & 2028
FIGURE 13 FIVE YEAR SURVIVAL RATE OF PANCREATIC NEUROENDOCRINE TUMOR BETWEEN 2010- 2016
FIGURE 14 INCIDENCE OF NEO-ENDOCRINE NEOPLASM IN CHINA, EUROPE AND U.S.
FIGURE 15 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET: BY CLASSIFICATION, 2020
FIGURE 16 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION, 2020-2028 (USD MILLION)
FIGURE 17 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET: BY CLASSIFICATION, CAGR (2021-2028)
FIGURE 18 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET: BY CLASSIFICATION, LIFELINE CURVE
FIGURE 19 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET: BY SITE, 2020
FIGURE 20 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET, BY SITE, 2020-2028 (USD MILLION)
FIGURE 21 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET: BY SITE, CAGR (2021-2028)
FIGURE 22 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET: BY SITE, LIFELINE CURVE
FIGURE 23 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET: BY GRADE, 2020
FIGURE 24 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET, BY GRADE, 2020-2028 (USD MILLION)
FIGURE 25 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET: BY GRADE, CAGR (2021-2028)
FIGURE 26 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET: BY GRADE, LIFELINE CURVE
FIGURE 27 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET: BY TYPE, 2020
FIGURE 28 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2020-2028 (USD MILLION)
FIGURE 29 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET: BY TYPE, CAGR (2021-2028)
FIGURE 30 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET: BY TYPE, LIFELINE CURVE
FIGURE 31 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET: BY ROUTE OF ADMINISTRATION, 2020
FIGURE 32 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2028 (USD MILLION)
FIGURE 33 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2021-2028)
FIGURE 34 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET: BY ROUTE OF ADMINSTRATION, LIFELINE CURVE
FIGURE 35 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET: BY END USER, 2020
FIGURE 36 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET, BY END USER, 2020-2028 (USD MILLION)
FIGURE 37 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET: BY END USER, CAGR (2021-2028)
FIGURE 38 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET: BY END USER, LIFELINE CURVE
FIGURE 39 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET: BY DISTRIBUTION CHANNEL, 2020
FIGURE 40 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2020-2028 (USD MILLION)
FIGURE 41 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)
FIGURE 42 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 43 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET: SNAPSHOT (2020)
FIGURE 44 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET: BY COUNTRY (2020)
FIGURE 45 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET: BY COUNTRY (2021 & 2028)
FIGURE 46 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET: BY COUNTRY (2021 & 2028)
FIGURE 47 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET: BY CLASSIFICATION (2021-2028)
FIGURE 48 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET: COMPANY SHARE 2020 (%)

Metodologia de Investigação
A recolha de dados e a análise do ano base são feitas através de módulos de recolha de dados com amostras grandes. A etapa inclui a obtenção de informações de mercado ou dados relacionados através de diversas fontes e estratégias. Inclui examinar e planear antecipadamente todos os dados adquiridos no passado. Da mesma forma, envolve o exame de inconsistências de informação observadas em diferentes fontes de informação. Os dados de mercado são analisados e estimados utilizando modelos estatísticos e coerentes de mercado. Além disso, a análise da quota de mercado e a análise das principais tendências são os principais fatores de sucesso no relatório de mercado. Para saber mais, solicite uma chamada de analista ou abra a sua consulta.
A principal metodologia de investigação utilizada pela equipa de investigação do DBMR é a triangulação de dados que envolve a mineração de dados, a análise do impacto das variáveis de dados no mercado e a validação primária (especialista do setor). Os modelos de dados incluem grelha de posicionamento de fornecedores, análise da linha de tempo do mercado, visão geral e guia de mercado, grelha de posicionamento da empresa, análise de patentes, análise de preços, análise da quota de mercado da empresa, normas de medição, análise global versus regional e de participação dos fornecedores. Para saber mais sobre a metodologia de investigação, faça uma consulta para falar com os nossos especialistas do setor.
Personalização disponível
A Data Bridge Market Research é líder em investigação formativa avançada. Orgulhamo-nos de servir os nossos clientes novos e existentes com dados e análises que correspondem e atendem aos seus objetivos. O relatório pode ser personalizado para incluir análise de tendências de preços de marcas-alvo, compreensão do mercado para países adicionais (solicite a lista de países), dados de resultados de ensaios clínicos, revisão de literatura, mercado remodelado e análise de base de produtos . A análise de mercado dos concorrentes-alvo pode ser analisada desde análises baseadas em tecnologia até estratégias de carteira de mercado. Podemos adicionar quantos concorrentes necessitar de dados no formato e estilo de dados que procura. A nossa equipa de analistas também pode fornecer dados em tabelas dinâmicas de ficheiros Excel em bruto (livro de factos) ou pode ajudá-lo a criar apresentações a partir dos conjuntos de dados disponíveis no relatório.